News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Applied NeuroSolutions, Inc. (APNS.OB) Announces Renewal of Alzheimer's Disease Drug Discovery Collaboration with Eli Lilly and Company (LLY)



12/8/2009 8:53:29 AM

VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTCBB:APSN)(www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today announced that Eli Lilly and Company (NYSE:LLY) has agreed to a one-year renewal of its drug discovery collaboration. Lilly will pay $250,000 to Applied NeuroSolutions for the one-year collaboration renewal.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES